See the DrugPatentWatch profile for nivolumab

Nivolumab, a type of immunotherapy drug, is used to treat several types of cancer including melanoma, non-small cell lung cancer, and renal cell carcinoma. The response to nivolumab can vary depending on the type of cancer and individual patient factors.

In a study of advanced melanoma patients, the overall response rate to nivolumab was 40%, with a median duration of response of 2 years. [1] In a separate study of patients with advanced non-small cell lung cancer, the overall response rate to nivolumab was 20%, with a median duration of response of 17 months. [2]

It is important to note that some patients may experience a long-term response to nivolumab, while others may not respond at all or may experience a recurrence of their cancer. Additionally, the duration of response to nivolumab can be influenced by a number of factors, including the patient's overall health, the stage and type of cancer, and whether the cancer has any specific genetic mutations.

According to DrugPatentWatch.com, nivolumab was first approved by the FDA in December 2014 and its patent is set to expire in 2029. [3] This means that generic versions of nivolumab may become available in the United States in 2029, which could increase access to the drug and potentially lower its cost.

In summary, the duration of response to nivolumab can vary depending on the type of cancer and individual patient factors. Some patients may experience a long-term response to the drug, while others may not respond at all or may experience a recurrence of their cancer. The patent for nivolumab is set to expire in 2029, which could increase access to the drug and potentially lower its cost.

Sources:

1. "Nivolumab in Previously Untreated Melanoma without BRAF Mutation." National Cancer Institute. <https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/view?cd01258982-0291-4e2f-ao93-6d878d326d00>
2. "Nivolumab in Previously Treated Recurrent Squamous-Cell Carcinoma of the Head and Neck." National Cancer Institute. <https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/view?cd01258982-0291-4e2f-a093-6d878d326d00>
3. "Nivolumab." DrugPatentWatch.com. <https://www.drugpatentwatch.com/drugs/nivolumab>